Andzonbio2’s website
1 known investors
AndzonBio2 develops early-stage, mechanism-based therapies targeting neuroinflammation as a driver of neurological and neurodegenerative diseases. The company pursues disease-modifying treatments for patients with brain disorders that have limited treatment options, working through academic science and partnerships.